Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Borthakur G, et al. Among authors: wright jj. Haematologica. 2011 Jan;96(1):62-8. doi: 10.3324/haematol.2010.030452. Epub 2010 Oct 15. Haematologica. 2011. PMID: 20952518 Free PMC article. Clinical Trial.
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J. Karp JE, et al. Among authors: wright jj. Blood. 2001 Jun 1;97(11):3361-9. doi: 10.1182/blood.v97.11.3361. Blood. 2001. PMID: 11369625 Free article. Clinical Trial.
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, Wright J, Kantarjian H. Cortes J, et al. Clin Cancer Res. 2004 May 15;10(10):3371-6. doi: 10.1158/1078-0432.CCR-03-0508. Clin Cancer Res. 2004. PMID: 15161691 Clinical Trial.
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS. Karp JE, et al. Among authors: wright jj. Clin Cancer Res. 2005 Dec 1;11(23):8403-12. doi: 10.1158/1078-0432.CCR-05-1201. Clin Cancer Res. 2005. PMID: 16322302 Clinical Trial.
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD. Dahut WL, et al. Among authors: wright jj. Clin Cancer Res. 2008 Jan 1;14(1):209-14. doi: 10.1158/1078-0432.CCR-07-1355. Clin Cancer Res. 2008. PMID: 18172272 Clinical Trial.
368 results